Democratic presidential nominee and former Secretary of State Hillary Clinton on Monday said she would continue to advance Vice President Biden's cancer "moonshot" initiative if she is elected.
Biden is leading a national effort announced in January by President Obama to find a cure for cancer.
Biden said his primary focus under the initiative is to eliminate barriers that prevent researchers from sharing data and increase public and private funding for cancer research.
Prior to a campaign event with Biden in Scranton, Pennsylvania, Clinton released a statement saying she would "take up the charge" to find a cure for cancer if she is elected president.
In her statement, Clinton called for "robust" federal funding. She urged Congress to approve Obama's nearly $1 billion funding request for the moonshot initiative, saying, "If we make the right investments today, we can save lives." Both Democratic and Republican lawmakers have supported the moonshot initiative.
Clinton also called for stronger public-private partnerships for medical research, citing the "unprecedented cooperation between federal agencies and leaders in the private and [not-for-profit] sectors" on cancer research.
Clinton said she wants to "strengthen the nation's entire scientific enterprise" and supports "bold ideas in research and science to go after diseases." She added, "We need to do more to build on these developments, advance our understanding, and develop more effective treatments."
Further, Clinton said she supports the National Breast Cancer Coalition's goal to end breast cancer by 2020.
Speaking at the rally Clinton suggested Biden could remain involved in the effort, saying, "If I'm elected president this fall, I'm going to ask for [Biden] to continue the important work he's begun and help us fight and defeat cancer" (Ferris, The Hill, 8/15; American Health Line, 4/6 [subscription required]; Scott, STAT News, 8/15; Owens, Morning Consult, 8/15).
Customize your moonshot: The personalized medicine investment playbook
To realize the benefits of personalized medicine, cancer providers have to make investments in laboratory capabilities, clinical decision support, rapid learning systems, patient education, and clinician training.
Join Advisory Board experts for a webconference Thursday, August 18, as we cover strategies to position your cancer program for success in the era of personalized medicine, including strategies to estimate volumes for molecular testing, guidance on providing clinical decision support, and considerations to evaluate data management partners.
Next in the Daily Briefing
NYT: Are medical errors really a leading cause of death?